Granisetron (Molecule of the Month for October 2006)
Granisetron isused to treat nausea and vomiting following chemotherapy. Its main affect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness.
Granisetron was developed by chemists working at the British drug company Beecham. It is now produced by Roche Laboratories under the trade name KytrilŪ. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA.
Granisetron is often intravenously about 30 minutes before beginning chemotherapy.
Update by Karl Harrison
(Molecule of the Month for October 2006 )